Omar Alqaisi | Skin Cancer | Best Researcher Award

Published on by Oncology

Mr. Omar Alqaisi | Skin Cancer | Best Researcher Award

Al-Zaytoonah University of Jordan | Jordan

Dr. Omar M. Alqaisi is a dedicated academic and researcher at Al-Zaytoonah University of Jordan whose scholarly contributions reflect a strong commitment to advancing healthcare through evidence-based nursing practice and oncology research. With 11 published documents, 46 citations, and an h-index of 3, his work demonstrates a consistent trajectory of academic growth and increasing impact in the fields of clinical nursing, psycho-oncology, and patient-centered care. His notable publication, “A Narrative Review of the Roles of Nursing in Addressing Sexual Dysfunction in Oncology Patients,” underscores his focus on addressing sensitive and underexplored areas of oncology, particularly the psychosocial and emotional well-being of cancer patients, while emphasizing the indispensable role of nurses in holistic recovery and improving quality of life. A hallmark of his career is his emphasis on interdisciplinary collaboration, evidenced by co-authorship with more than 100 researchers across multiple disciplines, reflecting his ability to foster teamwork and integrate diverse perspectives to address complex healthcare challenges. His research is characterized by analytical precision, ethical grounding, and a human-centered approach, aligning with global healthcare trends that prioritize compassion, inclusivity, and evidence-based interventions. Beyond individual studies, Dr. Alqaisi’s work contributes to the broader advancement of nursing education, clinical practice, and patient advocacy in oncology. His growing academic influence positions him as an emerging leader within regional and international research communities. With continued development in empirical methodologies, digital health innovations, and cross-cultural healthcare models, he is poised to expand his contributions to global nursing and oncology discourse. Dr. Alqaisi’s research not only advances academic understanding but also creates meaningful societal impact by emphasizing empathy, communication, and the integration of psychosocial care into clinical frameworks, exemplifying a new generation of scholars committed to bridging scientific innovation with humanistic healthcare practice.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

1. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, October 9). Immune checkpoint inhibitors in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Cancers, 17(19), 3272.

2. Alqaisi, O., Al-Ghabeesh, S., Tai, P., Wong, K., Joseph, K., & Yu, E. (2025, August 14). A narrative review of the roles of nursing in addressing sexual dysfunction in oncology patients. Current Oncology, 32(8), 457.

3. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, July 25). Immunotherapy in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Preprints, 202507.2063.v1.

4. Alqaisi, O., Subih, M., Joseph, K., Yu, E., & Tai, P. (2025, June). Oncology nurses’ attitudes, knowledge, and practices in providing sexuality care to cancer patients: A scoping review. Current Oncology, 32(6), 337.

5. Alqaisi, O. M., & Al-Ghabeesh, S. (2024, July 31). Quality of postoperative pain management in orthopedic patients and its impact on sleep quality and patient satisfaction: An integrative review. Cureus, 16(7), e65872.

Dr. Omar M. Alqaisi’s research advances the integration of compassionate, evidence-based nursing within oncology care, addressing both clinical and psychosocial patient needs. His work strengthens global healthcare practices by promoting interdisciplinary collaboration, enhancing patient quality of life, and shaping innovative models for holistic, human-centered medical care.

Melissa Christiaens | Cervical Cancer | Best Researcher Award

Published on by Oncology

Dr. Melissa Christiaens | Cervical Cancer | Best Researcher Award

Radiation-Oncology | University Hospitals Leuven | Belgium

Dr. Melissa Christiaens is a highly accomplished Radiation Oncologist recognized for her contributions to the advancement of radiotherapy and clinical oncology research. With extensive experience in oncological treatment, she has played a key role in integrating evidence-based radiotherapy techniques into modern cancer care. Her professional expertise spans across radiotherapy quality assurance, pediatric oncology, gynecologic cancers, and multidisciplinary tumor management. As an active member of several leading scientific organizations—including the European Society for Radiotherapy and Oncology, the Paediatric Radiation Oncology Society, the European Society of Gynaecological Oncology, the EuroEwing Consortium, and the Connective Tissue Oncology Society—she consistently collaborates in large-scale international research networks to improve patient outcomes and optimize therapeutic protocols. Her research interests focus on clinical trials in radiotherapy, immuno-oncology integration, and precision treatment strategies for rare and complex cancers. Dr. Christiaens has contributed to numerous high-impact peer-reviewed journals such as The Lancet, Radiotherapy and Oncology, BMC Cancer, and Gynecologic Oncology, where her publications have enhanced the scientific understanding of cancer treatment outcomes, safety, and innovation. Her research skills encompass clinical data interpretation, protocol development, treatment optimization, and evidence synthesis—supported by her commitment to maintaining the highest standards of clinical excellence. Throughout her career, she has demonstrated exceptional leadership in oncology research and education, promoting collaboration and innovation within the global cancer research community. Her achievements continue to inspire advancements in patient-centered cancer therapy and clinical radiobiology. Her enduring scientific legacy is reflected through 1,417 citations, 25 documents, and an h-index of 12, underscoring her influential role in advancing the frontiers of clinical radiotherapy, oncology innovation, and multidisciplinary cancer research.

Profiles: Google Scholar | Scopus | ResearchGate

Featured Publications

1. Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., & Christiaens, M., et al. (2021). MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): A multicentre prospective cohort study. The Lancet Oncology, 22(4), 538–547. Cited by: 613

2. Zhang, H., Ahearn, T. U., Lecarpentier, J., Barnes, D., Beesley, J., Qi, G., Jiang, X., & Christiaens, M., et al. (2020). Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 52(6), 572–581. Cited by: 466

3. Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., & Christiaens, M., et al. (2024). Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18). The Lancet, 404(10460), 1321–1332. 
Cited by: 323

4. Ajithkumar, T., Horan, G., Padovani, L., Thorp, N., Timmermann, B., Alapetite, C., & Christiaens, M., et al. (2018). SIOPE–Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy. Radiotherapy and Oncology, 128(2), 192–197. Cited by: 113

5. De Ruysscher, D., Sharifi, H., Defraene, G., Kerns, S. L., & Christiaens, M., et al. (2013). Quantification of radiation-induced lung damage with CT scans: The possible benefit for radiogenomics. Acta Oncologica, 52(7), 1405–1410. Cited by: 74

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Ping Dai | Cancer Therapy | Best Researcher Award

Published on by Oncology

Dr. Ping Dai | Cancer Therapy | Best Researcher Award

Tongji University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. PING DAI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ping Dai’s journey in medicine began with a Diploma of Higher Education in Clinical Medicine from Harbin University, followed by a Bachelor’s degree at Qiqihar Medical University. She excelled further with an Outstanding Master’s Degree in Oncology from Shihezi University, and culminated her academic path with a Doctorate in Molecular Radiation Oncology (Dr. Med, Magna Cum Laude) from the prestigious Heidelberg University in Germany—underscoring a profound commitment to academic excellence and clinical innovation.

🩺PROFESSIONAL ENDEAVORS

With over a decade of clinical and research experience, Dr. Dai currently serves as Assistant Director at the Shanghai Fourth People’s Hospital Affiliated to Tongji University. Her career spans multiple critical roles—oncologist, clinical researcher, and international doctoral candidate at the German Cancer Research Centre (DKFZ)—fusing global perspectives with localized healthcare innovation.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMARKERS  IN CANCER THERAPY

Dr. Dai’s research centers on radiation oncology, immunotherapy-related thyroid dysfunction, and tumor treating fields (TTFields). Notably, her recent studies explore PD-1/PD-L1 inhibitor-induced thyroid dysfunction as a biomarker for efficacy in advanced lung cancer therapy, published in BMC Cancer and Heliyon. She also leads groundbreaking simulation research on electrodynamic tumor interactions, merging clinical oncology with bioengineering insight.

🌍IMPACT AND INFLUENCE

Dr. Dai’s cross-continental experience—from China to Germany—bridges Eastern and Western oncology practices. Her insights contribute to both clinical protocol improvements and space-radiation biology, collaborating with institutions such as the European Space Agency and Heidelberg Ion Beam Therapy Center. She plays a vital role in shaping translational cancer science and space medicine.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Lead or corresponding author in high-impact journals: Cancer Letters (IF 9.7), APL Bioengineering (IF 6.6), and Frontiers in Oncology.

  • Honored with Outstanding Master’s Graduate award.

  • Latin honors “Magna Cum Laude” for doctoral studies in Germany.

  • Recognized as equal-first author and corresponding author in multiple prestigious publications.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Dai is establishing a legacy of translational research at the intersection of radiation therapy, immunology, and biomarker discovery. Her future pursuits aim to:

  • Advance predictive markers for immunotherapy outcomes.

  • Explore MSC-based interventions against radiation-induced myelotoxicity.

  • Lead multinational clinical collaborations in cancer therapy and space radiation countermeasures.

🧬CONCLUSION

Dr. Ping Dai is an emerging force in molecular oncology and translational medicine. With a rich academic foundation, strong clinical acumen, and a forward-thinking research vision, she is contributing impactful solutions to global oncology and radiobiology challenges.

📊🔬NOTABLE PUBLICATION:

Thyroid dysfunction as a predictor of PD-1/PD-L1 inhibitor efficacy in advanced lung cancer

Authors: Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
Journal: BMC Cancer
Year: 2025

Comprehensive Simulations of Intracellular Electric Fields during Exposure to Tumor Treating Fields (TTFields)

Authors: Kaida Liu, Ping Dai, Zirong Liu, Haohan Fang, Xing Li, Wei Gao
Journal: Frontiers in Oncology
Year: 2025 (Accepted)

Electrodynamic Interaction between Tumor Treating Fields and Microtubule Electrophysiological Activities

Authors: Xing Li, Kaida Liu, Haohan Fang, Zirong Liu, Yuchen Tang, Ping Dai
Journal: APL Bioengineering
Year: 2024

A theoretical study on evaluating brain tumor changes in tumor treating fields therapy by impedance detection

Authors: Xing Li, Kaida Liu, Haohan Fang, Rongzi Liu, Wei Gao, Ping Dai
Journal: Frontiers in Oncology
Year: 2024

Xinli Shi | Tumor | Best Researcher Award

Published on by Oncology

Ms. Xinli Shi | Tumor | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

SCOPUS ID

ORCID ID

🏥MS. XINLI SHI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Ms. Xinli Shi, a Chinese national, began her academic journey with a B.Sc. in Biochemistry from the Department of Bioengineering at Hebei University of Science and Technology (1996–2001). She deepened her expertise in immunological mechanisms with an M.Sc. in Medical Immunology (2003–2007) from Hebei Medical University, followed by a Ph.D. in Immunology (2011–2014) from the West China College of Basic Medicine and Forensic Medicine, Sichuan University—one of China’s top-tier medical schools.

🩺PROFESSIONAL ENDEAVORS

Prof. Shi’s academic career spans over two decades, reflecting progressive growth:

  • 2001–2013: She served at Hebei Medical University as a Teaching Assistant and then Lecturer, establishing foundational teaching experience.

  • 2013–2018: Appointed Associate Professor and Master’s Supervisor at the School of Basic Medicine, Hebei University of Chinese Medicine.

  • 2015–2017: Completed a Postdoctoral Fellowship at the Bethune International Peace Hospital, affiliated with the Third Military Medical University, focusing on advanced clinical research.

  • 2018–2023: Promoted to Professor and Doctoral Supervisor at Hebei University of Chinese Medicine.

  • 2023–Present: Serving as Professor and Doctoral/Master Supervisor at the Experimental Management Center, Shanxi University of Chinese Medicine.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Prof. Shi has made notable contributions in the field of tumor immunology, particularly within the tumor microenvironment, focusing on:

  • Autophagy

  • Drug Resistance

  • Restenosis

  • Inflammation-induced tumorigenesis

Her research explores how immune signaling and cellular stress responses shape tumor progression and therapeutic resistance, offering novel targets for immunomodulatory and chemotherapeutic interventions.

She has guided:

  • 3 Ph.D. students

  • 20+ M.D. students

  • Supervised postdoctoral fellows, actively fostering academic development and translational medicine research.

🌍IMPACT AND INFLUENCE

Prof. Shi’s work is highly regarded in both Western medicine and Traditional Chinese Medicine (TCM) circles. Her interdisciplinary approach integrates modern immunology with TCM principles, enabling translational applications in cancer and chronic disease therapy. She has been part of numerous provincial and national talent programs, contributing to science policy and medical education reform.

🏆RESEARCH GRANTS AND FUNDING

Prof. Shi has led 14 research projects, funded by prestigious national and provincial bodies. These include:

  • 2 National Natural Science Foundation of China (NSFC) grants (No. 81873112 & 82274315)

  • China Postdoctoral Science Foundation

  • Hebei Natural Science Foundation (multiple years)

  • Shanxi Science and Technology Department

  • Shanxi Provincial Administration of Traditional Chinese Medicine Innovation Team

🔹 Total grant portfolio spans over a decade, supporting basic, translational, and clinical research initiatives.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Prof. Shi’s career exemplifies academic excellence, clinical relevance, and mentorship. With growing involvement in Shanxi’s TCM innovation programs, she is positioned to pioneer integrative oncology in China—blending evidence-based traditional practices with cutting-edge immunotherapy research. Her future directions include:

  • Building innovation teams

  • Leading multi-center translational studies

  • Expanding doctoral and postdoctoral programs

  • Enhancing international collaborations in cancer research

🧬CONCLUSION

Prof. Xinli Shi stands at the confluence of biochemistry, medical immunology, and TCM oncology, with over 20 years of academic and clinical experience. Her dedication to tumor biology, immune modulation, and interdisciplinary research continues to shape the landscape of cancer therapeutics in China. As a mentor, scholar, and innovator, she contributes profoundly to the development of next-generation scientists and the advancement of personalized medicine.

📊🔬NOTABLE PUBLICATION:

RalB promotes lymph node metastasis in tongue squamous cell carcinoma

Authors: Y. Zhang, Yuman; Z. Liu, Zhihan; Y. Yang, Yanguang; L. Jia, Lifeng; X. Shi, Xinli
Journal: Genes and Genomics
Year: 2025

Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma

Authors: Y. Yang, Yanguang; S. Li, Shenghao; Q. Peng, Qing; Y. Zhang, Yuman; X. Shi, Xinli
Journal: Molecular Biology Reports
Year: 2024

Recent advances in graphitic carbon nitride-based heterojunction for biomedical applications

Authors: R. Jia, Ruilong; C. He, Cheng’en; S. Wang, Shanshan; G. Liao, Guangfu; X. Shi, Xinli
Citations: 3

Zhichen Xu | Radiation Oncology | Best Researcher Award

Published on by Oncology

Zhichen Xu | Radiation Oncology | Best Researcher Award

First Hospital of Quanzhou | China

AUTHOR PROFILE

SCOPUS ID

🏥MR. ZHICHEN XU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Mr. Xu Zhichen, originally from Putian and a member of the Han ethnic group, embarked on his medical journey at Luzhou Medical College, where he earned his Bachelor’s degree in Clinical Neurology (2005–2010). Driven by a growing interest in cancer care, he pursued a Master’s degree in Radiation Oncology at Fujian Medical University (2010–2013). His postgraduate training, conducted at the Fujian Provincial Tumor Hospital, laid the foundation for his specialization in radiotherapy.

🩺PROFESSIONAL ENDEAVORS

After completing his academic training, Mr. Xu underwent standardized residency training at Quanzhou First Hospital (2013.9–2014.9). Since September 2014, he has been an integral part of the hospital’s Radiotherapy Department, where he applies advanced radiotherapeutic techniques in clinical oncology. In 2024, he achieved the Vice Senior Certification in Radiotherapy, a testament to his professional growth and clinical mastery over the past decade.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON RADIATION ONCOLOGY

Mr. Xu specializes in Radiation Oncology, with a particular emphasis on esophageal cancer, focusing on enhancing therapeutic efficacy and patient outcomes. His clinical efforts are complemented by a strong commitment to research in radiotherapy optimization, side effect mitigation, and individualized treatment approaches.

🌍IMPACT AND INFLUENCE

A rising leader in regional cancer care, Mr. Xu is a core member of the Youth Committee of the Fujian Radiation Oncology Society. His selection for the “Hundred Talent Program” at Quanzhou First Hospital underlines his value as a future-forward clinician contributing to institutional development and innovation in cancer treatment.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Mr. Xu Zhichen aims to deepen his impact through work on precision radiotherapy, multidisciplinary cancer management, and the integration of AI and imaging technologies in clinical decision-making. He is committed to mentoring young oncologists and fostering collaborative research within and beyond Quanzhou.

🧬CONCLUSION

Mr. Xu Zhichen exemplifies the ideal blend of clinical expertise, research acumen, and leadership potential in the field of Radiation Oncology. With a focus on esophageal cancer, he continues to shape the future of radiotherapy in Fujian Province while contributing meaningfully to national and international cancer care standards.

 

📊🔬NOTABLE PUBLICATION:

A dynamic nomogram for predicting abdominal lymph node recurrence in patients with esophageal carcinoma

Authors: Xu Zhichen, Su Baoan, Lin Mingqiang, Xu Qinghua, Qu Mengke
Journal: Scientific Reports
Year: 2025

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

Published on by Oncology

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

MPMMCC, HBCH,Tata memorial centreVaranasi | India

AUTHOR PROFILE

GOOGLE SCHOLAR

🎓 EARLY ACADEMIC PURSUITS

Dr. Sadaf Haiyat laid a strong foundation for her medical career at Aligarh Muslim University (AMU), one of India’s premier institutions. She completed her MBBS in 2011 and pursued her MD in Pathology, graduating in 2016 with distinction. Her early education was marked by academic excellence, securing 75.5% in SSSC (10+2) with a distinction in Chemistry, and scoring a 99% merit in Science during high school at Nazareth Academy, Gaya.

🧑‍🏫 PROFESSIONAL ENDEAVORS

Dr. Haiyat has accrued over 11 years of rich experience in Anatomic and Clinical Pathology, including senior roles across reputed institutions such as J.N.M.C.H, AMU, Popular Multispeciality Hospital (Varanasi), Dr. Lal Path Labs (New Delhi), and currently serves as Assistant Professor and Consultant Oncopathologist at the Tata Memorial Centre/MPMMCC, Varanasi.

Her journey has spanned clinical diagnostics, academic teaching, lab administration, and quality assurance. She played a pivotal role in establishing a molecular pathology lab and actively leads EQAS audits and CAP/NABL compliance efforts.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON HEMATOLYMPHOID MALIGNANCY

Dr. Haiyat has significantly contributed to the diagnosis and characterization of hematolymphoid malignancies, integrating morphological, immunohistochemical, molecular, and cytogenetic techniques. She has independently handled bone marrow biopsies, hematopathology diagnostics, and real-time PCR testing, including for EGFR, HER2/neu, and EWSR1 alterations. Her role in initiating molecular diagnostics for precision oncology marks a critical contribution to personalized medicine in resource-optimized settings.

📚 ACADEMIC CONTRIBUTIONS AND CITES

  • Total Publications: 25 (including 19 in international journals)

  • Presentations: 34 papers/posters at national and international platforms

  • Conferences Attended: 44 (10 international, 34 national)

  • Notable Thesis: “Role of Syndecan-1 (CD138) as a Diagnostic Biomarker for Plasma Cells in Patients of Abnormal Uterine Bleeding”

Her research is regularly cited in hematology and oncopathology contexts, particularly for rare case diagnostics and biomarker identification.

🌏 IMPACT AND INFLUENCE

Her academic and diagnostic influence extends internationally, evidenced by:

  • Membership in prestigious bodies such as the International Society of Gynecological Pathology, Association of Molecular Pathology (AMP), and the British Association of Urologic Pathology.

  • Awarded the 2024 Global Pathology Education Award by the College of American Pathologists (CAP) — a global recognition of excellence and commitment to medical education and diagnostics.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Haiyat’s legacy is anchored in diagnostic precision, academic mentoring, and laboratory excellence. With a growing footprint in digital pathology, molecular diagnostics, and oncopathology, she is poised to lead next-generation pathology services, potentially extending to AI-assisted diagnostics, genomics-based therapeutic mapping, and international collaborations in cancer diagnostics.

She also mentors senior residents and scientific assistants, reflecting her commitment to nurturing the next wave of medical professionals.

🔚 CONCLUSION

Dr. Sadaf Haiyat stands out as a visionary pathologist, blending diagnostic expertise with academic vigor and clinical leadership. Her journey from a meritorious student to a recognized name in oncopathology reflects a commitment to excellence, education, and innovation. With a robust foundation, international accolades, and an eye toward the future of molecular and digital pathology, Dr. Haiyat is undeniably shaping the landscape of modern diagnostic medicine in India and beyond.

📊NOTABLE PUBLICATION:

Breast lymphomas: Clinical and pathological insights from a tertiary cancer care center in India
Journal: Indian Journal of Pathology and Microbiology
Year: 2024

Megaloblastic anemia: A common but often neglected cause of pyrexia of unknown origin
Journal: Journal of Translational Internal Medicine
Year: 2015

Epithelioid sarcoma: A diagnostic challenge of a rare presentation
Journal: Archives of International Surgery
Year: 2016

A Survey of Intestinal Lesions with Special Reference to Intestinal Tuberculosis in and Around Uttar Pradesh, India
Journal: International Journal of Current Microbiology and Applied Sciences
Year: 2015

Extradigital Glomus Tumour of Ankle in a Toddler: A Rare Case Report with Unusual Presentation
Journal: Journal of Medical and Surgical Pathology
Year: 2018

Prof. Linghua Li | Cancer Science | Best Researcher Award

Published on by Oncology

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

🌟Linghua Li, Ph.D., M.S., B.S. 🌍

Head Director, Infectious Disease Center
Guangzhou Eighth People’s Hospital, Guangzhou Medical University

👩‍⚕️Biography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth People’s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

  • National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
  • Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
  • NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

  • ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Li’s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

🧬Key Areas of Expertise

🔬 HIV Prevention and Treatment
🌿 Opportunistic Infections
📊 Clinical Trials and Data Analysis
🧑‍⚕️ Internal and Infectious Diseases

📚Academic Background

  • B.S., Clinical Medicine, Medical School of Peking University (1997)
  • M.S., Internal Medicine, Sun Yat-sen University (2008)
  • Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
  • Visiting Scholar, UNC-Chapel Hill (2012)
  • Visiting Scholar, Duke University (2014)

🔬Research Impact

🌟 Over 20 funded research projects
📄 Numerous publications in infectious disease and public health journals
📚 Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. 🌏✨

✨ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. 🌟🌍

📊🔬NOTABLE PUBLICATION:
  • Utilizing Protein–Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19
    • Authors: Peiyan Zheng, Baolin Liao, Jiao Yang, Hu Cheng, Zhangkai Cheng, Huimin Huang, Wenting Luo, Yiyue Sun, Qiang Zhu, Yi Deng, et al.
    • Journal: Microorganisms
    • Year: 2023

Dr Ghanshyam Ghelani | Bladder Cancer | Best Researcher Award

Published on by Oncology

Dr Ghanshyam Ghelani | Bladder Cancer | Best Researcher Award

SUNY Upstate Medical University | United States 

Author Profile

Scopus

ORCID Id

🩺Ghanshyam Ghelani, MD 💉

Hematology-Oncology Fellow & Clinical Investigator
SUNY Upstate Medical University, Syracuse, NY

🎓 Education

  • M.B.B.S. – B.J. Medical College, Ahmedabad, Gujarat, India (09/2002 – 03/2008)
    📚 Ranked in the top 10% of a class of 250 students.
  • Internal Medicine Residency – The Wright Center for Graduate Medical Education, Scranton, PA, USA (07/2013 – 06/2016)
    🏥 Completed residency at affiliate hospitals including Geisinger CMC and VA Medical Center.
    🏅 Awarded M.D. by New York State on November 16, 2016.
  • Hematology-Oncology Fellowship – SUNY Upstate Medical University, Syracuse, NY (07/2021 – 06/2024)
    💉 Active Member of the Transfusion Medicine Committee and Hematology-Oncology Representative of the Resident and Fellow Forum.

💼 Certifications and Licensure

  • Board Certification – The American Board of Internal Medicine
  • State License – New York: Full License # 285166
  • DEA Registration – FG6123385
  • Advanced Cardiac Life Support (ACLS) – Re-Certified on 10/09/2021

🌐 Professional Memberships

  • 👨‍⚕️ Member, American College of Physicians
  • 🇮🇳 Life Member, Gujarat Medical Council
  • 🩺 Member, American Medical Association (AMA)
  • 🧬 Member, American Society of Clinical Oncology (ASCO)
  • 🌍 Member, European Society for Medical Oncology (ESMO)
  • 🩸 Member, American Society of Hematology (ASH)

🔬 Research and Academic Work

Assistant Professor of Medicine & Clinical Investigator
SUNY Upstate Medical University (07/2016 – 06/2021)

  • Key Research Projects
    • 🧬 HPV-Positive Clinically Advanced Bladder Squamous Cell Carcinoma (aBSCC): Analyzed genomic alterations associated with HPV.
    • 🧑‍🔬 Metabolic Syndrome & Immunotherapy in NSCLC: Studied the impact of metabolic syndrome on outcomes with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).
    • 🩸 Peripheral Blood Biomarkers in Metastatic Melanoma: Identified biomarkers for treatment response and immune-related adverse events in patients treated with immunotherapy for stage-IV melanoma.

🏅 Awards

  • Ranked in the top 10% of the class during medical school. 🎖️

Dr. Ghanshyam Ghelani is a dedicated Hematology-Oncology fellow with expertise in internal medicine and a strong background in cancer research, particularly in genomic profiling, immunotherapy, and biomarker discovery. 🧬💡

 

🔍 Conclusion

Dr. Ghanshyam Ghelani is a highly accomplished medical professional, currently advancing his expertise as a Hematology-Oncology Fellow at SUNY Upstate Medical University. With a strong foundation in internal medicine and an impressive portfolio of research in cancer treatment and immunotherapy, Dr. Ghelani has made significant contributions to the field of oncology. His active involvement in professional societies and dedication to exploring novel cancer therapies highlight his commitment to improving patient outcomes through cutting-edge research and clinical practice. Dr. Ghelani’s journey reflects a deep passion for medicine, research, and innovation in cancer care. 💉🧬🌟

 

📊🔬NOTABLE PUBLICATION:

 

    • Radioimmunoconjugates in the Age of Modern Immuno-Oncology
      • Authors: Nasr, D., Kumar, P.A., Zerdan, M.B., Graziano, S., Lim, S.H.
      • Journal: Life Sciences
      • Year: 2022

     

    • HPV-Positive Clinically Advanced Squamous Cell Carcinoma of the Urinary Bladder (aBSCC): A Comprehensive Genomic Profiling (CGP) Study
      • Authors: Ghelani, G.H., Zerdan, M.B., Jacob, J., Bratslavsky, G., Basnet, A.
      • Journal: Urologic Oncology: Seminars and Original Investigations
      • Year: 2023

     

    • Breast Cancer Treatment: To Target or Not? That Is the Question
      • Authors: Stone, A., Lin, K.M., Ghelani, G.H., Graziano, S., Kotula, L.
      • Journal: Cancers
      • Year: 2023

     

    • Hematologic Abnormalities After COVID-19 Infection: A Case of Coombs-Negative Hemolytic Anemia and Thrombocytopenia
      • Authors: Siegenthaler, A.G., Ghelani, G., Brady, A., Loon, T., Madhira, B.R.
      • Journal: Journal of Investigative Medicine High Impact Case Reports
      • Year: 2023

     

    • Metabolic Syndrome Is Independently Associated with Improved Overall Survival to First-Line Therapy with Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
      • Authors: Bou Zerdan, M., Ashok Kumar, P., Barrios, D.M., Graziano, S., Lim, S.H.
      • Journal: Frontiers in Oncology
      • Year: 2023

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Published on by Oncology

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Stanford University School of Medicine | United States

Author Profile

Scopus

Orcid id

📚 Biography: Dr. Stavros Melemenidis

🎓 Education

  • DPhil in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2010-2015)
    • Mentors: Prof. Nicola Sibson, Prof. Ruth Muschel
    • Thesis: Development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis
  • M.Sc. in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2009-2010)
  • M.Sc. in Radiometrics – University of Liverpool, Dept. Physics, Liverpool, UK (2008-2009)
  • B.Sc. in Physics: Medical Applications – University of Liverpool, Dept. Physics, Liverpool, UK (2005-2008)
  • A.Eng. in PC Systems and Peripheral Equipment – IIEK Neapoleos, Technical College, Thessaloniki, Greece (1998-2000)
  • Cert. Medical Physics – UCLA, Dept. Radiation Oncology, Los Angeles, CA, USA (2022-2023)

🏢 Current Position

  • Director of Pre-clinical Radiotherapy – Dept. of Radiation Oncology, Stanford University (Jan 2023-present)
  • Research Scientist – Div. of Radiation Therapy, Stanford University (Feb 2020-present)

🔬 Research Experience & Skills

  • Stanford University, Dept. Radiation Oncology, Stanford, CA
    • Director of Pre-clinical Radiotherapy Core (Jun 2023-present)
      • Calibration of preclinical orthovoltage irradiators
      • Monthly and annual quality checks for dosimetric consistency
      • Innovation in animal radiation shielding via 3D design and additive manufacturing
    • Basic Life Research Scientist at Div. of Radiation Therapy (Jun 2020-present)
      • Pioneering preclinical ultra-high dose-rate (FLASH) irradiation experiments
      • Specializing in 3D-designed radiation shielding for animal safety
      • Expertise in dosimetry using radiochromic film and ion chambers
      • Development of animal models involving tumor implantation and microsurgical techniques
    • Postdoctoral Fellow (Feb 2016-Jun 2020)
      • Advisor: Edward E. Graves
      • Led development of in vivo mouse tumor models integrating imaging, radiotherapy, and immunotherapy
      • Specialized in ultrasound-guided injection techniques
      • Conducted research into immune cell migration with a focus on macrophage imaging
      • Evaluated radioprotective strategies for healthy tissue through drug development
    • Postdoctoral Fellow at University of Oxford, Dept. Radiation Oncology (Jan 2015-Sep 2015)
      • Advisor: Nicola R. Sibson
      • Designed and evaluated innovative imaging probes for metastasis detection and angiogenesis visualization
      • Developed dual MRI/PET probe for metastasis and MRI probe for angiogenesis
      • Managed international research collaboration with Duke University

📜 Selected Publications

  • In vivo PET detection of lung micrometastasis by targeting endothelial VCAM-1. Int J Mol Sci, 2024.
  • Multi-institutional audit of FLASH and conventional dosimetry with a 3D-printed anatomically realistic mouse phantom. Int J Radiat Oncol Biol Phys, 2023.
  • Exploring deep learning for estimating the isoeffective dose of FLASH irradiation from mouse intestinal histological images. J Radiat Oncol Biol Phys, 2023.
  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation. Integr Biol (Camb), 2023.
  • Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest, 2023.

🏆 Awards & Honors

  • Recognition of Excellent Research: Aegean Conferences: 12th International Conference on Complement Therapeutics, Rhodes, Greece, 2019
  • Poster Prize: Aegean Conferences: 3rd International Conference for Tumor Microenvironment and Cellular Stress, Greece, Mykonos, 2014

🗣️ Conference Presentations

  • Oral Presentation: Demonstrating FLASH effectiveness against CONV dose rates, 34th ACRO Summit, Orlando, FL, March 2024
  • Poster Presentation: Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation, 65th ASTRO Annual Meeting San Diego, USA, Oct 2023

📞 References

  • Prof. Billy W Loo Jr: Professor of Radiation Oncology (Radiation Therapy), Stanford University School of Medicine
  • Prof. Edward E Graves: Associate Professor of Radiation Oncology and Director of Molecular Imaging Program, Stanford University School of Medicine
  • Prof. Frederick M Dirbas: Associate Professor of Surgery (General Surgery), Stanford University School of Medicine

Dr. Stavros Melemenidis is a distinguished figure in radiation oncology, with a profound impact on preclinical radiotherapy and FLASH irradiation research. His contributions to innovative imaging techniques and his dedication to advancing cancer treatment methodologies are reflected in his extensive publication record and numerous accolades.

📊🔬Notable Publication: